Total Funding
29
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-17 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
235333
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.
Acquired by 
Brickell Biotech
About the Company
Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy.
Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for
animal health are on the market. The first human products are approaching.
